<DOC>
	<DOCNO>NCT00128999</DOCNO>
	<brief_summary>Lung cancer lead cause cancer-related mortality United States ( US ) Canada . Because high incidence mortality disease , small improvement management disease translate large number patient improved outcomes treatment . Radiation therapy widely use treat patient lung cancer . However , radiation dose tumor limit proximity normal structure tumor , lung , spinal cord esophagus . The normal structure must expose excessive radiation dos . A new technique , call intensity-modulated radiotherapy delivers radiation tumor normal structure around tumor expose less radiation previously achievable . This technique already use treat head neck cancer . This study use technique deliver intensified radiation lung tumor patient receive two cycle chemotherapy . A new imaging technique , call positron emission tomography ( PET ) , find sensitive specific detect extent tumor lung old imaging technique compute tomography ( CT ) . This study use PET CT target radiation beam . Following treatment , patient follow assess side effect normal tissue response tumor treatment .</brief_summary>
	<brief_title>Study Using Induction Chemotherapy Intensity-Modulated Radiation Therapy Guided Combined CT PET Imaging Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Hypothesis Objectives : The hypothesis respiratory gate IMRT escalate safely radiation dos NSCLC induction chemotherapy test . The intent study determine maximum tolerable dose radiotherapy NSCLC , use novel treatment planning technique accelerate fractionation , give state-of-the-art imaging guidance . Primary Objective : - To establish maximum tolerate dose radiotherapy assess treatment toxicity accord acute RTOG grade scale . Secondary Objectives : - To evaluate treatment toxicity combination regimen accord chronic RTOG grade scale ; - Quality Life : assess use EORTC QLQ-C30 LC13 ; - To determine progression-free survival regimen ; - To identify partial organ tolerance dos lung , esophagus heart . Schema Methods : Eligible patient consent receive two cycle cisplatin-vinorelbine chemotherapy . Thoracic radiotherapy give afterwards accord dose-escalating scale . Only one dose level open one time . Dose level 1 : 84 . Gy 35 fraction 7 wks ; Dose level 2 : 79.5 Gy 40 fraction 6 wks ; Dose level 3 : 75 . Gy 40 fraction 5 wks . Eligibility Criteria : - Patients histologically-proven , biopsy cytology , unresected NSCLC - Patients AJC Stage I-III detectable tumor encompass radiation therapy field - Patients positive supraclavicular node ( N3 ) malignant pleural effusion eligible . - Age &gt; = 18 - Karnofsky performance status &gt; = 70 - ANC &gt; 1.5 ; Plt &gt; 100,000 ; Hct &gt; 30 % ; AST ( SGOT ) &lt; 1.5 ULN ; serum creatinine &lt; 1.5 mg/dL - Patients must measurable disease CT PET image - Patients must FEV1 &gt; 1.0 L - Evaluation total lung volume receive 20 Gy ( V20 ) must &lt; 30 % ; mean esophageal dose must &lt; 32 Gy ; esophageal V 55 &lt; 28 % . - Patients must satisfactory IMRT plan prior start radiotherapy . Statistical Considerations Primary Endpoint : The frequency patient develop unacceptable ( grade 3 high ) toxicity accord RTOG acute toxicity scale attributable radiotherapy . Acute radiotherapy toxicity define toxicity occur within 90 day start radiotherapy . Sample Size : In order establish maximum tolerate dose ( MTD ) radiotherapy deliver use IMRT follow induction chemotherapy , acceptable morbidity criterion must define . Based Radiation Therapy Oncology Group ( RTOG ) 94-10 , dose limit toxicity ( DLT : define grade 3 4 non-hematologic toxicity ) rate study determine 40 % . After 7 evaluable patient follow minimum 90 day start radiation therapy , patient evaluate respect treatment morbidity . If acute dose limit toxicity first 5 patient ( 0/5 ) , current dose deem acceptable escalate . If 1 acute DLT observe first 5 patient ( 1/5 ) acute DLTs last two patient ( 0/2 ) , dose deem acceptable escalate . Otherwise current dose deem toxic escalation end . This design give least 90 % confidence true acute DLT rate give dose level less 40 % give dose level , probability escalate true toxicity rate 40 % high least 88 % . Safety Monitoring Stoppage Rules : An SAE untoward medical occurrence : - result death ; - life-threatening ( patient immediate risk death ) ; - require inpatient hospitalization prolongation exist hospitalization ; - result persistent significant disability/incapacity ; - congenital anomaly/birth defect ; - important medical event may immediately life-threatening result death hospitalization may jeopardize patient may require medical surgical intervention prevent one outcomes listed definition . Reporting SAEs follow : 1 . Complete Serious Adverse Event Report ; 2 . Fax Serious Adverse Event Report within 24 hour investigator 's designee 's knowledge event attention : Dr. Wilson Roa ( 780 ) 432-8517 ( tel ) ; ( 780 ) 432-8380 ( fax ) Dr. Don Yee ( 403 ) 944-2895 ( tel ) ; ( 403 ) 283-1651 ( fax ) ; 3 . Accrual may stop immediately indicate upon review confirmation SAE two PIs . Recruitment Reporting : The projection rate accrual base previous preliminary study . At rate , would take three month complete accrual 3 dose level . A three-month waiting period require prior dose escalation next level . Hence , estimate 7 month conservatively allow level , amount total 21 month complete accrual , treatment wait period primary endpoint . The first manuscript study complete end two year . Analysis report treatment result contain tabulation case enter excluded analysis , reason exclusion . Respective institutional accrual observe endpoint MTD , toxicity , progression-free survival quality life analyze .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Stage IIII Unresectable nonsmall cell lung cancer ( NSCLC ) EEV1 equal great 1.0L Positive supraclavicular noce ( N2 ) malignant pleural effusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>radiation therapy</keyword>
</DOC>